ONCOLYTICS BIOTECH INC
ONCYNasdaq
$0.85
↓ -3.4%Jul 17 close · end-of-day
Price
1Y↓ -31.7%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$81.8M
Enterprise Value
$76.3M
P/E
—
P/S
—
P/B
—
EV/EBITDA
—
PEG
—
FCF Yield
-24.6%
Dividend Yield
—
Revenue (TTM)
—
Net Income (TTM)
-$28.8M
Free Cash Flow (TTM)
-$20.1M
Gross Margin
—
Operating Margin
—
Net Margin
—
ROE
560.6%
ROIC
—
Debt / Equity
—
Net Cash
$5.5M
Return 1Y
-35.4%
Company profile
Oncolytics Biotech Inc. focuses on the discovery and development of pharmaceutical products for the treatment of cancer. Its lead product is pelareorep, an intravenously delivered immunotherapeutic agent. The company was incorporated in 1998 and is headquartered in Calgary, Canada.
- CEO
- Matthew C. Coffey
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 30
- Headquarters
- Alberta
- Website
- oncolyticsbiotech.com
Management & directors
- Kelly JaredChief Executive Officer
- Hagerman AllisonVP, Product Development
- Heineman Thomas CharlesChief Medical Officer
- Look KirkChief Financial Officer
- Aromando AndrewChief Business Officer
Roles derived from SEC Form 4 filings.
Earnings
ONCY Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue——
Diluted EPS-$0.08↑ +33.3%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2024 | FY2025 |
|---|---|---|
| Revenue | — | — |
| Gross profit | — | — |
| Operating income | -$25.5M | -$28.7M |
| Net income | -$22.8M | -$28.8M |
| Diluted EPS | -$0.30 | -$0.30 |
| Operating cash flow | -$19.9M | -$20.1M |
| Free cash flow | -$20.1M | -$20.1M |
| Gross margin | — | — |
| Operating margin | — | — |
| Net margin | — | — |
| Line item | Q1 '25 | Q1 '26 |
|---|---|---|
| Revenue | — | — |
| Gross profit | — | — |
| Operating income | -$5.0M | -$9.3M |
| Net income | -$4.7M | -$9.2M |
| Diluted EPS | -$0.06 | -$0.08 |
| Operating cash flow | -$4.7M | -$7.3M |
| Free cash flow | -$4.7M | -$7.3M |
| Gross margin | — | — |
| Operating margin | — | — |
| Net margin | — | — |
Company news
Jul 13, 2026
Jun 16, 2026
- 34d agoSector Update: Healthcare Stocks Advance in Afternoon Tradingfinance.yahoo.com
- 34d agoONCY Stock Surged Today – Here’s What Securing A Key Immunotherapy Patent Means For Oncolyticsstocktwits.com
- 34d agoOncolytics Biotech® Secures New U.S. Patent Protecting Commercial Manufacturing of Pelareorep into 2044finance.yahoo.com
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-03-12 | Kelly Jared· Chief Executive Officer | Buy | 5,050 | $0.96 | $4,848.00 | filing |
| 2026-03-11 | Parsons James T. | Buy | 10,000 | $1.03 | $10,300.00 | filing |
| 2026-02-12 | Seizinger Bernd R. | Buy | 40,000 | $0.85 | $33,864.00 | filing |
| 2026-02-12 | Andrews Patricia S | Buy | 35,400 | $0.86 | $30,291.78 | filing |
| 2026-02-12 | Pisano Wayne | Buy | 30,000 | $0.84 | $25,338.00 | filing |
| 2026-02-12 | Kelly Jared· Chief Executive Officer | Buy | 29,500 | $0.84 | $24,839.00 | filing |
| 2026-02-12 | Brown Deborah Margaret | Buy | 25,000 | $0.85 | $21,240.00 | filing |
| 2026-02-12 | Look Kirk· Chief Financial Officer | Buy | 12,000 | $0.84 | $10,104.00 | filing |
| 2026-02-12 | Heineman Thomas Charles· Chief Medical Officer | Buy | 12,132 | $0.83 | $10,033.16 | filing |
| 2026-02-12 | Hagerman Allison· VP, Product Development | Buy | 10,000 | $0.83 | $8,298.00 | filing |
| 2026-02-11 | Seizinger Bernd R. | Buy | 60,000 | $0.83 | $49,590.00 | filing |
| 2026-02-11 | Aromando Andrew· Chief Business Officer | Buy | 29,600 | $0.86 | $25,417.52 | filing |
| 2026-02-11 | Kelly Jared· Chief Executive Officer | Buy | 5,600 | $0.84 | $4,681.60 | filing |
| 2026-01-16 | Seizinger Bernd R. | Buy | 100,000 | $1.04 | $103,770.00 | filing |
Latest 14 transactions.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.